使用Withings睡眠垫连续监测评估OSA平均疾病缓解
这项初步研究前瞻性纳入29例接受CPAP或HGNS治疗的OSA患者,用Withings睡眠垫进行30天和90天连续家庭睡眠监测,计算整合疗效与依从性的平均疾病缓解(MDA)。90天MDA在CPAP组为36.05%、HGNS组为24.06%(p=0.20),而基于单夜睡眠研究或CPAP下载的MDA分别为81.72%和51.18%(p=0.002)。研究证明连续无创家庭监测计算MDA可行,比单夜研究更全面评估真实世界疗效。
要点
- Withings睡眠垫可连续无创家庭监测OSA治疗,用于计算MDA。
- 90天连续监测MDA在CPAP与HGNS组间无显著差异(p=0.20)。
- 单夜数据MDA显著高于连续监测,提示单夜评估可能高估疗效。
核心结论
- 通过Withings睡眠垫连续无创家庭监测计算MDA是可行的,能比单夜研究更全面评估OSA真实世界治疗有效性。
研究设计与样本
- 前瞻性初步研究,共纳入29例接受CPAP(15例)或HGNS(14例)治疗的OSA患者,平均年龄59.8岁,66%男性,93%白人。
主要发现
- 90天连续AHI监测计算的MDA在CPAP组为36.05%,HGNS组为24.06%(p=0.20)。
- 基于单夜睡眠研究(HGNS)或CPAP下载(CPAP)的MDA在CPAP组为81.72%(14.81),HGNS组为51.18%(26.69)(p=0.002)。
- 30天监测期间HGNS组每晚觉醒次数多于CPAP组(3.23 vs. 2.56,p=0.031),打鼾次数也更多(2.86 vs. 1.79,p=0.029)。
临床怎么用
- 连续家庭监测和MDA等整合指标可辅助OSA个性化治疗选择和长期管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This pilot study aims to demonstrate the feasibility of continuous sleep monitoring using the Withings Sleep Mat (WSM) and to illustrate Mean Disease Alleviation (MDA) as a potential metric for assessing real-world treatment effectiveness among patients with obstructive sleep apnea (OSA) treated with hypoglossal nerve stimulation (HGNS) or continuous positive airway pressure (CPAP). METHODS: Patients treated with CPAP or HGNS therapy were prospectively recruited. The WSM provided nightly estimations of sleep metrics including AHI, total sleep time, and other non-apneic metrics over 30- and 90-day periods. MDA integrating treatment efficacy and adjusted compliance was calculated as a composite measure of real-world treatment effectiveness. RESULTS: A total of 29 patients (mean age 59.8 years; 66% male; 93% White) were included, with 15 treated with CPAP and 14 with HGNS. The 90-day MDA, calculated using continuous AHI monitoring, was 36.05% for CPAP and 24.06% for HGNS (p = 0.20). Mean MDA using single-night sleep study (HGNS) or CPAP download (CPAP) was 81.72% (14.81) among CPAP patients and 51.18% (26.69) among HGNS patients (p = 0.002). HGNS patients experienced more awakenings (3.23 vs. 2.56, p = 0.031) and snoring episodes (2.86 vs. 1.79, p = 0.029) per night during the 30-day interval. CONCLUSION: This study demonstrates the feasibility of calculating MDA through continuous, non-invasive home monitoring using the WSA, offering a more comprehensive assessment of OSA treatment effectiveness than single-night studies alone. These findings support further evaluation of continuous home-based monitoring and integrated metrics like MDA to inform personalized therapy selection and long-term management.
引用
- Kaki PC, Childs M, Calotti R, et al. Continuous Sleep Monitoring Using the Withings Sleep Mat to Assess Mean Disease Alleviation in OSA. Laryngoscope. 2025. PMID: 41472338. doi:10.1002/lary.70352
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。